Amgen Buys Ilypsa for $420 Million
Filed in archive Corporate and Industrial News by ruth on June 06, 2007

(CKD) patients on hemodialysis.
ILY101 is an orally administered, non-absorbed polymeric agent that works by preventing the absorption of ingested phosphate. Studies suggest that ILY101 may have enhanced phosphate binding selectivity and capacity compared to currently available polymeric phosphate binding agents. ILY101 has completed Phase 2 trials in patients with CKD who are on hemodialysis.More details regarding the acquisition from Amgen's press release.
Permalink: Amgen Buys Ilypsa for $420 Million
Tags:
amgen biotech investment merger renal+disease kidney+disease 500+Internal+Server+Error+read+timeou
Trackback: http://www.creative-weblogging.com/cgi-bin/mt-tb.pl/74005







